Envestnet Portfolio Solutions Inc. Buys 23,240 Shares of Merck & Co., Inc. $MRK

Envestnet Portfolio Solutions Inc. lifted its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 28.3% in the second quarter, Holdings Channel.com reports. The fund owned 105,500 shares of the company’s stock after acquiring an additional 23,240 shares during the quarter. Envestnet Portfolio Solutions Inc.’s holdings in Merck & Co., Inc. were worth $13,557,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in MRK. Kingdom Financial Group LLC. bought a new position in shares of Merck & Co., Inc. in the 4th quarter worth about $25,000. Abound Financial LLC acquired a new stake in Merck & Co., Inc. during the fourth quarter worth approximately $26,000. Prosperity Bancshares Inc bought a new stake in Merck & Co., Inc. in the fourth quarter worth approximately $26,000. High Note Wealth LLC lifted its stake in Merck & Co., Inc. by 58.9% in the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after buying an additional 109 shares during the period. Finally, IFC & Insurance Marketing Inc. bought a new position in shares of Merck & Co., Inc. during the 4th quarter worth approximately $31,000. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Price Performance

Merck & Co., Inc. stock opened at $135.78 on Friday. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.06. Merck & Co., Inc. has a one year low of $77.58 and a one year high of $135.97. The firm has a market capitalization of $334.98 billion, a P/E ratio of 108.62, a PEG ratio of 5.85 and a beta of 0.19. The business has a fifty day moving average price of $125.54 and a 200-day moving average price of $119.94.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The business had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. During the same quarter last year, the company earned $2.13 EPS. The firm’s revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities research analysts forecast that Merck & Co., Inc. will post 2.77 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be issued a $0.85 dividend. This represents a $3.40 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 272.00%.

Insider Buying and Selling

In related news, EVP David Michael Williams sold 52,847 shares of Merck & Co., Inc. stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the completion of the sale, the executive vice president owned 31,716 shares of the company’s stock, valued at approximately $4,084,069.32. This trade represents a 62.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jennifer Zachary sold 80,315 shares of the business’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total value of $10,718,839.90. Following the transaction, the executive vice president owned 45,509 shares of the company’s stock, valued at approximately $6,073,631.14. The trade was a 63.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 228,238 shares of company stock valued at $29,977,783 in the last ninety days. 0.17% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. Bank of America raised their target price on Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Guggenheim boosted their price target on shares of Merck & Co., Inc. from $145.00 to $146.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Weiss Ratings downgraded Merck & Co., Inc. from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday. Finally, Citigroup assumed coverage on shares of Merck & Co., Inc. in a research report on Wednesday, May 6th. They set a “neutral” rating and a $125.00 target price for the company. Fifteen investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $135.50.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst upgrade and higher valuations: Daiwa Securities upgraded MRK from “neutral” to “outperform” and set a $143 price target. Other analysts have raised fair-value estimates into the $140–$155 range, citing pipeline progress, business-development activity and late-stage therapies. Daiwa Securities upgrade
• Positive Sentiment: Business momentum remains supportive: MRK recently touched a record high, while Keytruda demand, oncology products, new launches and Animal Health helped drive quarterly revenue of $16.61 billion, above the $16.37 billion consensus estimate. The company also exceeded earnings expectations and reported 5.1% year-over-year revenue growth. Merck fair value and pipeline progress
• Positive Sentiment: Income and diversification appeal: Merck declared its regular $0.85 quarterly dividend, or $3.40 annualized, while potential expansion of ENFLONSIA for RSV prevention could broaden growth beyond oncology.
• Neutral Sentiment: Insider selling warrants monitoring: EVP Chirfi Guindo sold 10,000 shares for $1.35 million, following substantial sales by executives Jennifer Zachary and Richard Deluca. Each executive retained a meaningful stake, so the transactions may reflect personal financial decisions rather than a deteriorating outlook. Merck insider selling report
• Negative Sentiment: Keytruda concentration is a future risk: Patent expiration and increasing competition could pressure Merck’s largest growth driver. Investors will need evidence that the pipeline and newer products can offset eventual Keytruda sales declines. Keytruda growth outlook

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.